Evidence map›Paper›PMID 41771842›Full record

Trial reportNutrition & diabetes2026

Heterogeneous effect of saxagliptin on glucose fluctuation and β-cell function in T1DM: a multicentre, randomised trial.

Yun Shi, Min Shen, Yong Gu, Yang Chen, Kuanfeng Xu, Ji Hu, Chen Fang, Heming Guo, Ning Xu, Guofeng Wang and 11 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02307695 (The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02307695 phase4unknown statusnot on this map

The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes

TypeinterventionalSponsorNanjing Medical UniversityRan2014 to 2017Enrolled184ConditionsType 1 DiabetesArmsSaxagliptin, Insulin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yun Shi *Department of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Min Shen *Department of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yong GuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yang ChenDepartment of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Kuanfeng XuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Ji Huthe Second Affiliated Hospital of Soochow University, Suzhou, China.
Chen Fangthe Second Affiliated Hospital of Soochow University, Suzhou, China.
Heming Guothe Second Affiliated Hospital of Soochow University, Suzhou, China.
Ning XuLianyungang Clinical College of Nanjing Medical University(The Affiliated Hospital of Kangda College of Nanjing Medical University), Lianyungang, China.
Guofeng WangLianyungang Clinical College of Nanjing Medical University(The Affiliated Hospital of Kangda College of Nanjing Medical University), Lianyungang, China.
Weiping LuThe Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Nanjing, China.
Sha TaoYangpu Hospital, Tongji University, Shanghai, China.
Songqing ZhaoThe Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Nanjing, China.
Chengxia FangThe Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Nanjing, China.
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rengna YanDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rui SunDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Li QianSir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Chenguang WuEndocrinology Department, Affiliated People's Hospital, Jiangsu University, Zhenjiang, China.
Hui JiangEndocrinology Department, Affiliated People's Hospital, Jiangsu University, Zhenjiang, China.
Tao YangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. yangt@njmu.edu.cn.ORCID 0000-0001-6375-3622

Funding

AstraZeneca
6 · The paper itself

Abstract

BACKGROUND AND

aimsWe aimed to explore whether saxagliptin, a dipeptidyl peptidase-IV inhibitor, could ameliorate glucose fluctuations and maintain β-cell function in T1DM. METHODS AND

resultsA multicentre, open-label, randomised trial was performed, including 184 T1DM patients from six medical centres. These patients received insulin with or without saxagliptin at 5 mg per day for 24 weeks. The primary endpoint was the change from the baseline value of the MAGE, as measured by a CGMS after 24 weeks. The secondary endpoints included the change from baseline value of islet function during the 3-hour BMTT, HbA1c, and insulin dosage. The exploratory analysis was the influence of SNPs in the incretin-related genes on saxagliptin treatment outcomes. No differences were observed between the two groups in MAGE after treatment for 24 weeks. The change of C-peptide CLINICALTRIALS: Gov number, NCT02307695.

Indexed as

AdamantaneBlood GlucoseDiabetes Mellitus, Type 1DipeptidesDipeptidyl-Peptidase IV InhibitorsInsulin-Secreting CellsAdultContinuous Glucose MonitoringC-PeptideFemaleGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansHypoglycemic AgentsInsulinMaleAdamantaneBlood GlucoseC-PeptideDipeptidesDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHypoglycemic AgentsInsulinsaxagliptin

Identifiers

PMID41771842
PMCPMC12987927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.